PR Release – BioCina awarded Grants to develop enabling technologies for manufacture of precision mRNA vaccines

MIAMI and ADELAIDE, Australia, April 27, 2023 /PRNewswire/ — BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a $5.0m AUD grant under the Federal Government’s Medical Research Future Fund (MRFF) Grants scheme to fund work with its industry partners to develop enabling technologies for manufacture of precision mRNA vaccines. The grant has […]

Q&A: BioCina’s new CEO Mark Womack on the CDMO he says is ‘worth traveling over’

March 29, 2023 Published on Endpoints News A handful of CDMOs have made changes at the top over the past few weeks, including Genezen and Curia. That also includes Australian CDMO BioCina, which announced last week that Mark Womack would be taking the helm. Womack previously served as chief business officer at AGC Biologics, CEO […]

PR Release – Mark W. Womack Joins BioCina as CEO

PR Release - Mark W. Womack Joins BioCina as CEO (MIAMI and ADELAIDE March 14, 2023) BioCina, a leading contract development and manufacturing organization (CDMO) has appointed Mark W. Womack as CEO. Womack will be responsible for the continued growth, commercial strategy and organizational culture of BioCina. This follows the appointment of founding CEO, Ian Wisenberg, to [...]

GPN Vaccines

Case Study GPN Vaccines It can take several months—even years—to successfully develop a groundbreaking pharmaceutical product. Moving the product into manufacturing and clinical trials can take even longer. There's good news: working with an experienced CDMO with the capacity to speed up the process can save months of development time. BioCina recently developed a robust [...]

Manufacturing Partnerships: Don’t Underestimate the Importance of Collaboration

Manufacturing Partnerships: Don’t Underestimate the Importance of Collaboration   Tim Hirst, CEO of GPN Vaccines, recently spoke with Outsourced Pharma about how BioCina quickly developed a new manufacturing process for their groundbreaking pneumococcal vaccine. Read the article in Outsourced Pharma: Click here  When selecting a CDMO, the most important traits to consider are speed, collaboration, and […]

Mythbusting: The pharmaceutical development industry is slow-moving.

An interview with Phillip Elliott, Associate Director R&D It’s true that modern medicines require on average more than a decade to develop but Dr. Phillip Elliott argues, it’s actually moving pretty fast.  Our drug development process is actually sensible.  It’s wise to invest in an adequate amount of testing and development before a medicine is widely […]

SA’s own needle-free Covid vaccine to start human trials

June 20, 2022 Published in Sunday Mail, by Brad Crouch Excerpts copied below. Read the full article in Sunday Mail at the link at the bottom of the page. A new Covid-19 vaccine designed and manufactured in Adelaide starts human trials this week with potential to become a major export earner – and it doesn’t […]

Plasmid DNA Manufacturing- Insights from BioProcess International 2022

The widespread use of pDNA in cell and gene therapy (CGT) is driving increasing demand—and it’s no surprise it was one of the hottest topics at recent events including the recent BioProcess International (BPI) conference, what’s known as the largest bioprocessing event in the world.  Sessions covering topics as diverse as cell and gene therapy, […]

PR Release – BioCina announces opening of new GMP plasmid DNA manufacturing suite

(SAN DIEGO and ADELAIDE June 13, 2022) BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and suitably scaled [...]

BioCina: Developing technologies to support the next generation of mRNA-based therapies

June 1, 2022 Published on Success Stories austrade.gov.au Australian biologics manufacturer BioCina has plans to further develop its state-of-the-art facility to enable it to make the next generation of mRNA vaccines and other mRNA-based therapies possible. Backed by Australian Government financial support, BioCina is partnering with the University of Adelaide and US-based Cytiva to speed […]